Quantec clinical trial presents new hope for acne sufferers

New Hope for Acne Sufferers

Quantec presents results of clinical trial at New Zealand Dermatological Society Annual Meeting

Hamilton, 11 July 2013 - New Zealand-based dairy biotechnology company, Quantec Ltd, presented the results of its US clinical trial on acne to dermatologists at the New Zealand Dermatological Society Annual Meeting in Coolum, Australia on July 11-12.

In the clinical trial conducted at a clinical research facility in California, USA and completed in February 2013, Quantec’s patented complex of bioactive milk proteins - called IDP® - was the active ingredient in a specially formulated skin cream that went head-to-head in a double blind study against a premium, US-based clinical brand of acne treatment cream (containing 2% salicylic acid plus retinal).

At the conclusion of the 42-day trial involving 84 subjects, both the premium brand of acne treatment cream and the IDP®-based cream showed statistically equivalent results in terms of total reduction in acne lesions.

The IDP®-based cream, however, also showed a major improvement of over 52% in reduction of redness and inflammation.

As part of the clinical assessment, the IDP®-based cream also passed specific testing for use on subjects with sensitive skin, making it the superior performer of the two products and ideal for users with hyper-reactive and sensitive skin.

Founder and Managing Director of Quantec Ltd, Dr Rod Claycomb, explains that, “IDP® is a unique and naturally derived complex of bio-proteins. These bio-proteins have unique properties, which make them very powerful against certain types of disease-causing bacteria which leave the natural and beneficial bacteria of the skin largely unaffected.

“By leaving these natural and beneficial bacteria active on the skin, IDP® creates a perfect scenario for treatment and management of acne. In addition, the IDP® bio-proteins signal directly to inflamed tissues and cells to quell the inflammatory response. IDP® contains what we refer to as ‘Triple-A’ activity - antibacterial, anti-inflammatory and antioxidant.”

Dr Claycomb said Quantec was founded on the value that all its products are proven through science and, as such, it was important to the company to unveil IDP® and its efficacy as an acne treatment to dermatologists first prior to developing and launching a commercial acne product.

“Quantec is a company committed to developing high-value bioactives from natural products, which are backed with solid science. It has taken our research and development team seven years to create IDP® and now prove its efficacy as an acne treatment.

“Therefore, it was important to us to detail the results of our clinical trial and gain the backing of industry-leading dermatologists prior to a commercial product launch.”

IDP® clinical results at a glance
• Study compared IDP®-based cream with premium, US-based clinical brand of acne treatment cream
• Statistically equivalent results in terms of total reduction in acne lesions
• IDP®-based cream showed over 52% improvement in reduction of redness and inflammation
• IDP®-based cream passed specific testing for use on subjects with sensitive skin

About Quantec Ltd
Based at the Waikato Innovation Park in Hamilton, New Zealand, Quantec is a company specialising in the discovery and commercialisation of high-value bioactives from natural products. Quantec discovered and patented its novel milk fraction, comprised of native immune defense proteins (IDP®), that has proven antimicrobial and anti-inflammatory properties.

www.idpbio.com
www.quantec.co.nz

ENDS

© Scoop Media